Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria.
Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria.
复制标题
DOI：
10.1002/gcc.22846
复制
发表时间：
2020-08
期刊：
影响因子：
--
通讯作者：
Antonescu CR
中科院分区：
文献类型：
--
作者：
Antonescu CR
软组织肿瘤 (STT) 分类的最新突破是与 NTRK 和其他激酶相关融合相关的肿瘤数量显着增加。这不仅对于诊断目的很重要，而且因为它为靶向治疗开辟了新途径。事实上，最近的临床试验已经显示出对多种肿瘤类型的显着益处，促使 NTRK 抑制剂被批准用于晚期/转移性 NTRK 重排肿瘤的临床应用。尽管有这些治疗机会，但在前瞻性识别这些新兴的激酶融合阳性 STT 组织学亚型方面仍面临诊断挑战。这在一定程度上归因于它们广泛的形态谱、不同的恶性肿瘤风险和非特异性免疫特征。因此，需要提出病理标准和免疫组织化学检测的建议，以改进分类并简化一小部分潜在候选者，以进行进一步的分子验证。本概述总结了与 NTRK 和其他激酶融合相关的各种 STT 的关键组织学特征，它们似乎具有相似的形态学谱。免疫组织化学显示，许多此类肿瘤，无论激酶融合类型如何，都明显表现出 S100 和 CD34 的共表达；因此总结了与泛 NTRK 和 NTRK1 免疫染色的实用性相关的问题。最后，我讨论了验证性分子检测的作用，以及在某些情况下这可能具有预后价值。本综述旨在对当前文献进行批判性总结，强调病理学标准，以提高对这一新兴且复杂的激酶融合相关 STT 群体的认识。
A recent breakthrough in the classification of soft tissue tumors (STT) has been a significant expansion in the number of neoplasms associated with NTRK and other kinase related fusions. This is important not only for diagnostic purposes, but also because it opens new avenues for targeted therapy. Indeed, recent clincal trials have shown significant benefit across multiple tumor-types, prompting approval of NTRK inhibitors for clinical use in the setting of advanced/metastatic NTRK-rearranged neoplasms. Despite these therapeutic oportunities, diagnostic challenges have transpired in recognizing these emerging new histologic subtypes of kinase fusions positive-STT prospectively. This, in part, is attributable to their wide morphologic spectrum, variable risk of malignancy, and non-specific immunoprofile. As such, recommendations for pathologic criteria and immunohistochemical testing are needed to improve classification and streamline the small subset of potential candidates for further molecular validation. This overview summarizes the key histologic features of various STT associated with NTRK and other kinase fusions, which appear to share a similar morphologic spectrum. Immunohistochemically, many of these tumors, regardless of the kinase fusion type, notably show co-expression of S100 and CD34; issues related to the utility of pan-NTRK and NTRK1 immunostaining are therefore summarized. Finally, I discuss the role of confirmatory molecular testing and how, in some instances, this may also be of prognostic value. This review is intended as a critical summary of the current literature to emphasize pathologic criteria for improving recognition of this emerging and complex group of kinase fusion associated STT.
登录
查看更多内容
DOI：
10.1097/pas.0000000000001055
发表时间：
2018-06
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Chiang S;Cotzia P;Hyman DM;Drilon A;Tap WD;Zhang L;Hechtman JF;Frosina D;Jungbluth AA;Murali R;Park KJ;Soslow RA;Oliva E;Iafrate AJ;Benayed R;Ladanyi M;Antonescu CR
通讯作者：
Antonescu CR
影响因子：
4.1
作者：
Ameline, Baptiste;Saba, Karim H.;Baumhoer, Daniel
通讯作者：
Baumhoer, Daniel
DOI：
10.1016/s1470-2045(18)30119-0
发表时间：
2018-05
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Laetsch TW;DuBois SG;Mascarenhas L;Turpin B;Federman N;Albert CM;Nagasubramanian R;Davis JL;Rudzinski E;Feraco AM;Tuch BB;Ebata KT;Reynolds M;Smith S;Cruickshank S;Cox MC;Pappo AS;Hawkins DS
通讯作者：
Hawkins DS
影响因子：
7.3
作者：
Haller, Florian;Knopf, Jasmin;Agaimy, Abbas
通讯作者：
Agaimy, Abbas
DOI：
10.1002/gcc.22671
发表时间：
2018-12
期刊：
Genes, chromosomes & cancer
影响因子：
--
作者：
Suurmeijer AJH;Dickson BC;Swanson D;Zhang L;Sung YS;Cotzia P;Fletcher CDM;Antonescu CR
通讯作者：
Antonescu CR